林丹

【摘要】 目的 探讨两种新辅助化疗对乳腺癌临床治疗的疗效。方法 70例乳腺癌中晚期患者作为研究对象， 通过随机数字表法将其分为研究组与对照组， 各35例。对照组患者采取TAC（多西他赛+吡柔比星+环磷酰胺）方案进行新辅助化疗， 研究组患者采取TEC（多西他赛+表柔比星+环磷酰胺）方案进行新辅助化疗， 比较两组患者的临床疗效以及不良反应发生情况。结果 研究组患者总有效率为88.6%， 对照组为82.9%， 两组总有效率比较差异无统计学意义（P>0.05）；研究组患者不良反应发生率与对照组患者比较， 差异无统计学意义（P>0.05）。结论 两种新辅助化疗方案治疗乳腺癌具有显著的疗效， 且不良反应发生率低， 值得在临床上推广及应用。

【关键词】 新辅助化疗；乳腺癌；疗效

DOI：10.14163/j.cnki.11-5547/r.2016.29.012

Observation of curative effect by two neoadjuvant chemotherapy measures in clinical treatment of breast cancer LIN Dan. Breast Center， Chaozhou City Peoples Hospital， Chaozhou 521000， China

【Abstract】 Objective To investigate curative effect by two neoadjuvant chemotherapy measures in clinical treatment of breast cancer. Methods A total of 70 patients with moderate and advanced breast cancer as study subjects were divided by random number table into research group and control group， with 35 cases in each group. The control group received TAC （docetaxel+pirarubicin+cyclophosphamide） regimen for neoadjuvant chemotherapy， while the research group received TEC （docetaxel+epirubicin+cyclophosphamide） regimen for neoadjuvant chemotherapy. Clinical effects and adverse reactions were compared between the two groups. Results The research group had total effective rate as 88.6%， which was 82.9% in the control group. There was no statistically significant difference of total effective rate between the two groups （P>0.05）. The difference of incidence of adverse reactions had no statistical significance between the two groups （P>0.05）. Conclusion Both neoadjuvant chemotherapy measures contains precisely curative effect， along with low incidence of adverse reactions. It is worth clinical promotion and application.

【Key words】 Neoadjuvant chemotherapy； Breast cancer； Curative effect

乳腺癌是临床上常见的恶性肿瘤疾病， 采取新辅助化疗是治疗乳腺癌的重要方法[1]。新辅助化疗也被称为术前化疗、诱导化疗、首次化疗等， 是表示在局部治疗之前采取的化学药物治疗[2]。通过新辅助化疗能有效的缩小肿瘤、降低临床分期、提高保乳成功率、协助分析肿瘤对化疗药物的敏感性等诸多优点， 在临床上得到了广泛的应用[3]。但目前采取的化疗方案和化疗周期的选择尚没有统一的标准[4]。临床上治疗乳腺癌通常采取蒽环类药物治疗， 蒽环类的药物代表有多柔比星、表柔比星、吡柔比星， 而多柔比星的心脏毒性非常大， 在临床使用中受到了一定的限制。本文通过分析多西他赛+吡柔比星+环磷酰胺方案与多西他赛+表柔比星+环磷酰胺方案对中晚期乳腺癌患者进行化疗， 比较两种新辅助化疗的疗效， 现报告如下。